BR112021022099A2 - Derivados de amino quinazolina como inibidores de p2x3 - Google Patents
Derivados de amino quinazolina como inibidores de p2x3Info
- Publication number
- BR112021022099A2 BR112021022099A2 BR112021022099A BR112021022099A BR112021022099A2 BR 112021022099 A2 BR112021022099 A2 BR 112021022099A2 BR 112021022099 A BR112021022099 A BR 112021022099A BR 112021022099 A BR112021022099 A BR 112021022099A BR 112021022099 A2 BR112021022099 A2 BR 112021022099A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- quinazoline derivatives
- inhibitors
- amino quinazoline
- relates
- Prior art date
Links
- CZAAKPFIWJXPQT-UHFFFAOYSA-N quinazolin-2-amine Chemical class C1=CC=CC2=NC(N)=NC=C21 CZAAKPFIWJXPQT-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 2
- 102100040460 P2X purinoceptor 3 Human genes 0.000 abstract 2
- 101710189970 P2X purinoceptor 3 Proteins 0.000 abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19177604 | 2019-05-31 | ||
| EP19201168 | 2019-10-02 | ||
| PCT/EP2020/064914 WO2020239952A1 (en) | 2019-05-31 | 2020-05-28 | Amino quinazoline derivatives as p2x3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021022099A2 true BR112021022099A2 (pt) | 2021-12-28 |
Family
ID=70861506
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021021738A BR112021021738A2 (pt) | 2019-05-31 | 2020-05-28 | Derivados de amino quinazolina como inibidores de p2x3 |
| BR112021022099A BR112021022099A2 (pt) | 2019-05-31 | 2020-05-28 | Derivados de amino quinazolina como inibidores de p2x3 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021021738A BR112021021738A2 (pt) | 2019-05-31 | 2020-05-28 | Derivados de amino quinazolina como inibidores de p2x3 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20230092892A1 (enExample) |
| EP (2) | EP3976179A1 (enExample) |
| JP (3) | JP7644029B2 (enExample) |
| KR (2) | KR20220016499A (enExample) |
| CN (3) | CN113891745B (enExample) |
| AU (2) | AU2020281923A1 (enExample) |
| BR (2) | BR112021021738A2 (enExample) |
| CA (2) | CA3139018A1 (enExample) |
| CL (1) | CL2021003165A1 (enExample) |
| CO (1) | CO2021017031A2 (enExample) |
| GE (2) | GEP20257823B (enExample) |
| IL (1) | IL288405A (enExample) |
| MA (2) | MA56022A (enExample) |
| MX (2) | MX2021014115A (enExample) |
| PE (1) | PE20220934A1 (enExample) |
| PH (1) | PH12021552881A1 (enExample) |
| SA (1) | SA521430920B1 (enExample) |
| SG (1) | SG11202112187YA (enExample) |
| WO (2) | WO2020239952A1 (enExample) |
| ZA (1) | ZA202108273B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66105B1 (sr) | 2019-05-31 | 2024-11-29 | Janssen Pharmaceutica Nv | Inhibitori malih molekula nf-kb koji indukuju kinazu |
| US20230212169A9 (en) * | 2019-05-31 | 2023-07-06 | Chiesi Farmaceutici S.P.A. | Pyridopyrimidines derivatives as p2x3 inhibitors |
| JP7644029B2 (ja) | 2019-05-31 | 2025-03-11 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | P2x3阻害剤としてのアミノキナゾリン誘導体 |
| AU2020282759A1 (en) | 2019-05-31 | 2021-12-23 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| WO2022063205A1 (zh) * | 2020-09-24 | 2022-03-31 | 中国医药研究开发中心有限公司 | 芳基甲酰胺类化合物及其制备方法和医药用途 |
| US20240336606A1 (en) * | 2020-10-20 | 2024-10-10 | Suzhou Zelgen Biopharmaceuticals Co., Ltd. | Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof |
| WO2022112491A1 (en) * | 2020-11-27 | 2022-06-02 | Chiesi Farmaceutici S.P.A. | (aza)quinoline 4-amines derivatives as p2x3 inhibitors |
| WO2022112490A1 (en) * | 2020-11-27 | 2022-06-02 | Chiesi Farmaceutici S.P.A. | Amino quinazoline derivatives as p2x3 inhibitors |
| CN112661803A (zh) * | 2020-12-17 | 2021-04-16 | 上海药明康德新药开发有限公司 | DNA编码化合物库构建中On-DNA 4-胺基喹唑啉化合物的合成方法 |
| US11673876B2 (en) | 2020-12-22 | 2023-06-13 | Mekanistic Therapeutics Llc | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors |
| WO2022171118A1 (zh) * | 2021-02-10 | 2022-08-18 | 石药集团中奇制药技术(石家庄)有限公司 | 一种具有抗肿瘤活性的化合物及其用途 |
| CN115677601B (zh) * | 2021-07-29 | 2025-06-03 | 石药集团中奇制药技术(石家庄)有限公司 | 一种具有抗肿瘤活性的化合物及其用途 |
| WO2024235225A1 (zh) * | 2023-05-15 | 2024-11-21 | 苏州泽璟生物制药股份有限公司 | 取代嘧啶并环类抑制剂及其制备方法和应用 |
| WO2024240728A1 (en) | 2023-05-22 | 2024-11-28 | Chiesi Farmaceutici S.P.A. | Process and intermediates for the preparation of a p2x3 inhibitor |
| WO2024240727A1 (en) | 2023-05-22 | 2024-11-28 | Chiesi Farmaceutici S.P.A. | Salts of amino quinazoline derivatives |
| WO2025101598A1 (en) * | 2023-11-07 | 2025-05-15 | Zeno Management, Inc. | Bi-cyclic pyrimidine compounds, methods and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH31122A (en) * | 1993-03-31 | 1998-02-23 | Eisai Co Ltd | Nitrogen-containing fused-heterocycle compounds. |
| JP4342007B2 (ja) | 1998-08-10 | 2009-10-14 | 大日本住友製薬株式会社 | キナゾリン誘導体 |
| CA2557372C (en) * | 2004-03-05 | 2013-01-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
| ATE537169T1 (de) * | 2005-08-15 | 2011-12-15 | Hoffmann La Roche | Piperidin- und piperazinderivate als p2x3- antagonisten |
| MX2008002733A (es) | 2005-09-01 | 2008-03-26 | Hoffmann La Roche | Diaminopirimidinas como moduladores p2x3 y p2x2/3. |
| WO2008000645A1 (en) | 2006-06-29 | 2008-01-03 | F. Hoffmann-La Roche Ag | Tetrazole-substituted arylamides |
| US8653091B2 (en) | 2007-04-02 | 2014-02-18 | Evotec Ag | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof |
| CN101677569B (zh) | 2007-04-17 | 2014-01-22 | 伊沃泰克股份公司 | 2-氰基苯基稠合杂环化合物及其组合物和用途 |
| JP5539235B2 (ja) | 2008-02-29 | 2014-07-02 | エボテック・アーゲー | アミド化合物、組成物およびそれらの使用 |
| JP5608655B2 (ja) | 2008-09-18 | 2014-10-15 | エヴォテック アーゲー | P2x3受容体活性のモジュレーター |
| EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
| KR101685862B1 (ko) * | 2012-12-27 | 2016-12-20 | 에프. 호프만-라 로슈 아게 | Comt 억제제 |
| TWI637949B (zh) | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| US20170239249A1 (en) * | 2014-09-30 | 2017-08-24 | Bristol-Myers Squibb Company | Quinazoline-based kinase inhibitors |
| WO2016084922A1 (ja) | 2014-11-28 | 2016-06-02 | 塩野義製薬株式会社 | 1,2,4-トリアジン誘導体およびその医薬組成物 |
| JPWO2016088838A1 (ja) | 2014-12-04 | 2017-09-14 | 塩野義製薬株式会社 | プリン誘導体およびその医薬組成物 |
| DK3587417T3 (da) | 2014-12-09 | 2022-03-28 | Bayer Ag | 1,3-thiazol-2-yl-substituerede benzamider |
| WO2017011729A1 (en) | 2015-07-16 | 2017-01-19 | Patara Pharma, LLC | Combination therapies for the treatment of lung diseases |
| WO2017058645A1 (en) | 2015-09-29 | 2017-04-06 | Afferent Pharmaceuticals, Inc. | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
| EP4050005B1 (en) * | 2015-11-25 | 2024-12-25 | Convergene Llc | Bicyclic bet bromodomain inhibitors and uses thereof |
| ES2800339T3 (es) * | 2016-06-30 | 2020-12-29 | Gilead Sciences Inc | 4,6-diaminoquinazolinas como moduladores de cuna y métodos de uso de los mismos |
| EP3497087B1 (en) * | 2016-08-15 | 2021-11-10 | Neupharma, Inc. | Pyrrolo[1,2-c]pyrimidine, imidazo[1,5-c]pyrimidine, quinazoline, purine and imidazo[1,5-a][1,3,5]triazine derivatives as tyrosine kinase inhibitors for the treatment of cancer |
| WO2018115380A1 (en) | 2016-12-22 | 2018-06-28 | Boehringer Ingelheim International Gmbh | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| WO2018204775A1 (en) * | 2017-05-05 | 2018-11-08 | Hepanova, Inc. | Amino-aryl-benzamide compounds and methods of use thereof |
| JP7644029B2 (ja) | 2019-05-31 | 2025-03-11 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | P2x3阻害剤としてのアミノキナゾリン誘導体 |
| US20230212169A9 (en) | 2019-05-31 | 2023-07-06 | Chiesi Farmaceutici S.P.A. | Pyridopyrimidines derivatives as p2x3 inhibitors |
-
2020
- 2020-05-28 JP JP2021570930A patent/JP7644029B2/ja active Active
- 2020-05-28 CA CA3139018A patent/CA3139018A1/en active Pending
- 2020-05-28 MA MA056022A patent/MA56022A/fr unknown
- 2020-05-28 WO PCT/EP2020/064914 patent/WO2020239952A1/en not_active Ceased
- 2020-05-28 US US17/615,056 patent/US20230092892A1/en active Pending
- 2020-05-28 US US17/615,017 patent/US12466820B2/en active Active
- 2020-05-28 JP JP2021570931A patent/JP7641917B2/ja active Active
- 2020-05-28 KR KR1020217043074A patent/KR20220016499A/ko active Pending
- 2020-05-28 CN CN202080039837.0A patent/CN113891745B/zh active Active
- 2020-05-28 PE PE2021001962A patent/PE20220934A1/es unknown
- 2020-05-28 GE GEAP202015818A patent/GEP20257823B/en unknown
- 2020-05-28 AU AU2020281923A patent/AU2020281923A1/en active Pending
- 2020-05-28 MX MX2021014115A patent/MX2021014115A/es unknown
- 2020-05-28 AU AU2020285336A patent/AU2020285336A1/en active Pending
- 2020-05-28 EP EP20728765.7A patent/EP3976179A1/en active Pending
- 2020-05-28 MA MA056021A patent/MA56021A/fr unknown
- 2020-05-28 MX MX2021014113A patent/MX2021014113A/es unknown
- 2020-05-28 CN CN202410508911.9A patent/CN118239931A/zh active Pending
- 2020-05-28 BR BR112021021738A patent/BR112021021738A2/pt unknown
- 2020-05-28 CN CN202080040266.2A patent/CN114269432B/zh active Active
- 2020-05-28 CA CA3139019A patent/CA3139019A1/en active Pending
- 2020-05-28 KR KR1020217043072A patent/KR20220016498A/ko active Pending
- 2020-05-28 SG SG11202112187YA patent/SG11202112187YA/en unknown
- 2020-05-28 EP EP20728766.5A patent/EP3976180A1/en active Pending
- 2020-05-28 PH PH1/2021/552881A patent/PH12021552881A1/en unknown
- 2020-05-28 GE GEAP202515818A patent/GEAP202515818A/en unknown
- 2020-05-28 WO PCT/EP2020/064913 patent/WO2020239951A1/en not_active Ceased
- 2020-05-28 BR BR112021022099A patent/BR112021022099A2/pt unknown
-
2021
- 2021-10-26 ZA ZA2021/08273A patent/ZA202108273B/en unknown
- 2021-11-22 SA SA521430920A patent/SA521430920B1/ar unknown
- 2021-11-25 IL IL288405A patent/IL288405A/en unknown
- 2021-11-29 CL CL2021003165A patent/CL2021003165A1/es unknown
- 2021-12-14 CO CONC2021/0017031A patent/CO2021017031A2/es unknown
-
2025
- 2025-02-27 JP JP2025029719A patent/JP2025098014A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022099A2 (pt) | Derivados de amino quinazolina como inibidores de p2x3 | |
| SA519402319B1 (ar) | Rho- مشتقات أميد التيروسين كمثبطات لإنزيم الكيناز | |
| MX2019005526A (es) | Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa. | |
| NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
| NO20076093L (no) | Substituerte amidderivater som proteinkinaseinhibitorer | |
| EA202092678A1 (ru) | 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон | |
| BR112014007721A2 (pt) | processos para preparar compostos úteis como inibidores de atr quinase | |
| BR112015012366A8 (pt) | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido | |
| BR112018011046A2 (pt) | agonistas receptores de piperidinona formil peptí-deo 2 e de formil peptídeo 1 | |
| BR112021020279A2 (pt) | Derivados de piridopirimidinas como inibidores de p2x3 | |
| BR112017001860A2 (pt) | peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal | |
| BR112014013958A8 (pt) | ácidos piperidinila naftilacéticos | |
| MX387125B (es) | Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma. | |
| BR112012007635A2 (pt) | derivados de feniloxadiazol como inibidores de pgds | |
| MX2023005801A (es) | Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3). | |
| BRPI0509720A (pt) | derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina | |
| BRPI0511424A (pt) | composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para a preparação de um composto | |
| MX2023005805A (es) | Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3). | |
| MX2023005803A (es) | Derivados de amino-quinazolina como inhibidores del purinorreceptor 3 p2x (p2x3). | |
| BR112019001217A2 (pt) | peptídeos cíclicos como antagonistas de receptor de c5a | |
| MX2021015553A (es) | Inhibidores de arginasa novedosos. | |
| BR112022011901A2 (pt) | Peptídeo macrocíclico, e, composição farmacêutica | |
| EA202193300A1 (ru) | Производные аминохиназолина в качестве p2x3 ингибиторов | |
| MX2023005867A (es) | Derivados de dihidrofuropiridina como inhibidores de la cinasa rho. | |
| MX2023005866A (es) | Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |